221 related articles for article (PubMed ID: 29486199)
1. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract][Full Text] [Related]
2. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
3. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
4. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
5. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
6. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
7. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
[TBL] [Abstract][Full Text] [Related]
8. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
[TBL] [Abstract][Full Text] [Related]
11. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
[TBL] [Abstract][Full Text] [Related]
12. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis.
Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
[TBL] [Abstract][Full Text] [Related]
13. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
14. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
[TBL] [Abstract][Full Text] [Related]
18. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract][Full Text] [Related]
19. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355
[TBL] [Abstract][Full Text] [Related]
20. Hypo-methylation mediates chromosomal instability in pancreatic NET.
Marinoni I; Wiederkeher A; Wiedmer T; Pantasis S; Di Domenico A; Frank R; Vassella E; Schmitt A; Perren A
Endocr Relat Cancer; 2017 Mar; 24(3):137-146. PubMed ID: 28115389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]